Abstracts Archive - Page 201 of 2607 - ACR Meeting Abstracts

Abstract Number: 2619 • ACR Convergence 2024
Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients
Tali Eviatar¹, Iftach Sagy², Elad Brav², Amir Bieber³, Victoria Furer⁴ and Ori Elkayam⁵, ¹Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, ²Soroka Medical Cenrter, beer sheva, Israel, ³Emek Medical Center, Clalit Health Services, Raanana, Israel, ⁴Tel Aviv Medical Center, Tel Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
Abstract Number: 2693 • ACR Convergence 2024
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Ellen Romich¹, Joshua Baker², Ian Green², Rennie Rhee², Carol McAlear², Ulrich Specks³, Rona Smith⁴, David Jayne⁴ and Peter Merkel², and the RITAZAREM Investigators, ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, MN, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses are common in ANCA-associated vasculitis (AAV), both i) during maintenance treatment after induction of remission, and ii) after immunosuppressive treatment is discontinued. Relapses…
Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…
Abstract Number: 2520 • ACR Convergence 2024
Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019
Peter Merkel¹, Yi Peng², Patrick Zueger², Clara Ziadeh³, Ana B. Romero⁴, Richard Thielen³ and Denise Kruzikas³, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc, North Chicago, IL, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis affecting individuals aged ≥50 years. Over 80% of patients with GCA are aged ≥70 years, reflecting a…
Abstract Number: PP10 • ACR Convergence 2024
Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally
Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY
Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…
Abstract Number: 2629 • ACR Convergence 2024
Deciphering Salivary Gland Inflammation in Sjögren’s Syndrome Reveals Shared and Autoantibody-Specific Immune Cell Heterogeneity
Jun Inamo¹, Masaru Takeshita², Katsuya Suzuki², Kazuyuki Tsunoda², Satoshi Usuda², Junko Kuramoto², Tsutomu Takeuchi³ and Yuko Kaneko⁴, ¹University of Colorado School of Medicine, Aurora, CO, ²Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ³Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, JP, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Sjögren's syndrome (SS) is an autoimmune disease characterized by progressive immune cell-mediated destruction of the exocrine glands. SS patients have distinct clinical phenotypes based…
Abstract Number: 2530 • ACR Convergence 2024
Single-cell Multi-omics Analysis of Reactive Lymph Nodes, Affected Tissues, and Blood Reveals a Naive-like CD4+TRAIL+ T Cell Population That Differentially Directs Effector Anti-nuclear Antigen Reactive Responses in Patients with Sjogren’s Syndrome and Systemic Sclerosis
Theodoros Ioannis Papadimitriou¹, Prashant Singh², Arjan van Caam³, Madelon Vonk⁴, Irene E. van der Horst-Bruinsma⁵, Peter van der kraan³, Erik Aarntzen⁶, Martijn Huijnen⁷, Hans Koenen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ³Radboudumc, Department of Rheumatology, Nijmegen, Netherlands, ⁴Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Radboudumc, Department of Medical Imaging, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands
Background/Purpose: Recognition of self-peptides by autoreactive CD4+ T-cells is central to the disruption of immune tolerance. Although systemic autoimmune diseases such as Sjogren’s syndrome (SjS)…
Abstract Number: PP03 • ACR Convergence 2024
How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities
Shelley Fritz, Global Healthy Living Foundation, Kalaheo, HI
Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…
Abstract Number: 2523 • ACR Convergence 2024
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
Sema Kaymaz-Tahra¹, Ozun Bayindir Tsechelidis², Burak Ince³, Ozlem Ozdemir-Isik⁴, Muhammet Emin Kutu⁵, Ozlem Karakas⁶, Tuba Demirci-Yildirim⁷, Zeliha Ademoglu⁸, Elif Ediboglu⁹, Burcu Ceren Uludogan¹⁰, Nazife Sule yaşar Bile¹⁰, Timucin Kasifoglu¹¹, Servet Akar¹², Hakan Emmungil⁸, Fatos Onen⁷, Ahmet Omma¹³, Nilüfer Alpay Kanıtez¹⁴, Ayten Yazici¹⁵, Ayse Cefle¹⁵, Murat Inanc³, Kenan Aksu¹⁶, Gokhan Keser¹⁷, Haner Direskeneli¹⁸ and Fatma Alibaz Öner¹⁸, ¹Bahcesehir University Faculty of Medicine, Istanbul, Turkey, ²Ottawa University, Ottawa, ON, Canada, ³Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Ankara City Hospital, Ankara, Turkey, ⁷Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ⁸Trakya University, Edirne, Turkey, ⁹Mayo Clinic, Rochester, MN, ¹⁰Osmangazi University Faculty of Medicine, Rheumatology, Eskişehir, Turkey, Eskisehir, Turkey, ¹¹Osmangazi University Faculty of Medicine, Eskisehir, Turkey, ¹²Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ¹³Ankara Bilkent City Hospital, Ankara, Turkey, ¹⁴Koc University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey, ¹⁵Kocaeli University Faculty of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ¹⁶Ege University Faculty of Medicine, Izmir, Turkey, ¹⁷Ege University School of Medicine, Rheumatology, İzmir, Turkey, Izmir, Turkey, ¹⁸Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to…
Abstract Number: 2653 • ACR Convergence 2024
Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis
Elaine Yung¹, Xiaoxuan Liu², Bin Huang³, Michael Wagner¹, Minal Aundhia², Chen Chen⁴ and hermine brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cin, OH, ⁵Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: When uncontrolled, JIA is associated with short-term and long-term complications that affect the patient’s quality of life. A common goal of treatment is to…
Abstract Number: 2670 • ACR Convergence 2024
Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle
Cecilia Leijding¹, Suchada Kaewin², Kristofer Andreasson¹, Tomas Schiffer¹, Angeles Galindo-Feria³, Begum Horuluoglu¹, Mattias Carlstrom¹, Stefano Gastaldello¹, Helene Alexanderson⁴, Ingrid Lundberg⁵ and Daniel Andersson⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, ³Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁶Karolinska Institutet, Solna, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune inflammatory muscle disorders characterized by symmetrical skeletal muscle weakness and accelerated fatigue. Although signs…
Abstract Number: 2540 • ACR Convergence 2024
Characterizing the Functional Role of Type I Interferons in Inflammatory Arthritis
Mary Huang, Richard Bell, Toolika Singh and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation due to cellular infiltration and inflammatory mediators. Type I interferons (IFN) have…
Abstract Number: 2498 • ACR Convergence 2024
The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis
Veronica Pulito-Cueto¹, Joao Carlos Batista-Liz¹, Laura Carmen Terron², Iván Fernández Rengel³, María Sebastián Mora-Gil⁴, María Teresa Leonardo⁵, Ana Peñalba⁵, Luis Martín-Penagos⁶, Lara Belmar-Vega⁷, Cristina Gomez-Fernandez⁸, Ligia Gabrie-Rodriguez⁹, Rafael Gálvez Sánchez⁹, Luis Caminal-Montero¹⁰, Ana Turrion Nieves¹¹, Patricia Quiroga Colina¹², Esther Vicente-rabaneda¹³, Belén Sevilla-Pérez¹⁴, José Luis Callejas¹⁵, Eduardo Andrés-León², Javier Martin¹⁶, Ana María Marquez¹⁷, Santos Castañeda¹³, Ricardo Blanco-Alonso¹⁸ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Unidad de Bioinformática, Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, Granada, Spain, ³Bioinformatics Unit, Institute of Parasitology and Biomedicine López-Neyra (IPBLN), CSIC, GENYO, Cen, Granada, Spain, ⁴Immunopathology Group, IDIVAL, Santander, Spain, ⁵Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, ⁸Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ¹¹Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹³Hospital Universitario de La Princesa, Madrid, Spain, ¹⁴Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁵Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ¹⁶Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, ¹⁷Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Nephritis is the main cause of long-term morbidity and mortality in patients with Immunoglobulin-A vasculitis (IgAV) [1, 2]. Unfortunately, sensitive, specific, and non-invasive biomarkers…
Abstract Number: 2494 • ACR Convergence 2024
Clinical Characteristics, Predictors for Mortality and Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score on Survival in ANCA-associated Vasculitis in Hong Kong : A Multi-centre Retrospective Cohort Study
Ka Ho Yeung and Kit Yu Young, Caritas Medical Centre, Hong Kong, Hong Kong
Background/Purpose: To describe the clinical profile and predictors of mortality of AAV patients in Hong Kong. To compare the accuracy of the latest Five-factor Score…
Abstract Number: 2521 • ACR Convergence 2024
Clinicopathologic Associations Between Macrophage Location and Functional Profile in Giant Cell Arteritis
Michael Putman¹, Nader Khalidi², Carol Langford³, Curry Koening⁴, Christian Pagnoux⁵, David Cuthbertson⁶, Carol McAlear⁷ and Peter Merkel⁷, and the Vasculitis Clinical Research Consortium (VCRC), ¹The Medical College of Wisconsin, Milwaukee, WI, ²McMaster University, Hamilton, ON, Canada, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of Texas Dell Medical School, Austin, TX, ⁵Mount Sinai Hospital, Toronto, ON, Canada, ⁶University of South Florida, Tampa, FL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Macrophages play a central role in the pathogenesis of giant cell arteritis (GCA), but few studies have correlated macrophage phenotype or topography from temporal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].